Small cell carcinoma of the uterine cervix with cerebellar metastasis: A special case report with literature review

J.H. Zhu1, 2, Q.C. Hu2, K. Gu1, 2*, C. Shen3, R. Yang3, S.J. Ji2, Q.Q. Che2

1Department of Oncology, Nanjing Medical University, Nanjing, China
2Department of Radiation Oncology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital (East Branch)
3Department of Obstetrics and Gynecology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital (East Branch)

ABSTRACT

Background: Small cell carcinoma of the uterine cervix is a highly malignant form of cancer in women, characterized by its high propensity for rapid extra-pelvic distant metastasis and poor prognosis. The best treatment strategy for this type of cancer is still controversial. Case presentation: We report here a case of small cell carcinoma of the uterine cervix treated by extensive total hysterectomy followed by adjuvant chemoradiotherapy. A 45-year-old Chinese woman was diagnosed with stage IIA small cell carcinoma of the uterine cervix. The patient suffered from head metastasis following a diagnosis made fifteen months prior. Conclusion: We describe the optimal treatment and prognostic factors of this tumour. The stage of the tumour, main treatment, prognostic factors and outcome of this disease are presented with a review of the related literature.

Keywords: Cerebellar metastasis, small cell carcinoma, uterine cervix, treatment, prognostic factor.

INTRODUCTION

Small cell carcinoma of the uterine cervix (SCCC) is a highly malignant form of uterine cervix cancer. It has a low incidence rate that only comprises 1%-3% cervical carcinomas (1). The mean annual incidence for small cell carcinoma was 0.06 per 100,000 women compared to 6.6 and 1.2 for squamous cell carcinoma and adenocarcinoma, respectively (2). Because of the rarity of this disease, there is a paucity of information about the prognostic factors associated with survival. Moreover, optimal treatment strategies have not yet been clarified.

Similar to small cell carcinoma of the lung (SCLC), SCCC has a high propensity for rapid extra-pelvic distant metastasis to the lung, liver, brain, bone and lymph nodes, even in early stages. Thus, compared with other common histological types such as squamous cell carcinoma or adenocarcinoma, the outcome for patients with SCCC is poor. For all stages, 5-year survival rates range from 11% to 54%. Five-year survival for patients with disease limited to the pelvis is estimated to be 30%, in contrast to survival for patients with extensive disease, who rarely survive beyond 2 years following diagnosis (3). In 1957, Reagan et al. first described small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix, an extrapolmonary variant of small cell cancer (4).

CASE PRESENTATION

A 45-year-old Chinese woman presenting
with a 3-week history of pelvic discomfort visited our hospital in June 2015. Gynaecological examination showed an endocervical mass, 3 cm × 2 cm × 2 cm in size. Pelvic MRI showed an irregular soft tissue mass, 2.8 cm × 2.5 cm × 2.7 cm, at the internal orifice of the cervix. This tumour extended upward towards the lower body of the uterus, and multiple enlarged lymph nodes could be seen in the pelvic cavity. Human papillomavirus detection was positive for HPV-18. A chest CT scan revealed no lung metastasis. According to the clinical and radiological findings, the tumour was assigned to stage IIA according to the International Federations of Gynaecology and Obstetrics. The patient was treated with extensive total hysterectomy plus bilateral adnexectomy and high ligation of the bilateral infundibulopelvic ligament combined with pelvic cavity lymph node dissection on June 11, 2015 (figure 1). Pathology confirmed the tumour was SCC. The wall of the cervix was involved, and tumour thrombus was found in the veins. Eleven lymph nodes were metastasized, including two left common iliac lymph nodes, four right pelvic lymph nodes and five left pelvic lymph nodes. Immunohistochemically, SCLC was positive and NSE, Syn, ck18, CGA, CD56, and P63 were partly positive. Moreover, P53 was positive intermittently and Ki67 was 60% (figure 2). The patient received external radiotherapy on July 10, 2015. The specific plan of the treatment is described as follows: intensity-modulated radiation therapy (IMRT) 6 MV X-ray PTV (pelvic lymph node) 5000cGy/25f/36d. She also underwent the first cycle of concurrent adjuvant chemotherapy using a regimen of etoposide (0.17 g/day, days 1-3) and cisplatin (0.4 g/day, days 1-3) on July 12, 2015. During the first period of chemotherapy, bone marrow depression (grade IV) occurred, but the syndrome was relieved after symptomatic treatment. Then, on July 24, 2015, the second cycle of concurrent adjuvant chemotherapy in a regimen of etoposide (0.17 g/day, days 1-5) and cisplatin (0.35 g/day, days 1-3) was administered. The patient still suffered from bone marrow depression. Therefore, in the third, fourth, fifth and last cycle of chemotherapy, a regimen of etoposide (0.15 g/day, days 1-3) and cisplatin (0.35 g/day, days 1-3) was used. The patient received 6 cycles of chemotherapy in total. However, cerebellar metastasis occurred fifteen months after the SCC diagnosis. The cerebellar metastasis detected by CT was located in the left cerebellum, approximately 3 cm in diameter (figure 3). There was no other metastasis in this patient, particularly in the lungs (figure 4).

Figure 1. MRI showed a mass in the left cerebellum, about 3 cm in diameter a in the coronal position with contrast, b in the sagittal position with contrast, c in the axial position with contrast. d and e diffusion-weighted transverse MR image of the mass.
Figure 2. Neuroendocrine carcinoma of the cervix. Pathologically, small hyperchromatic cells with scant cytoplasm and typical brisk mitotic a. Immunohistochemically, b. NSE, c. Syn, d. CGA, e. CD56 are partly positive and f. Ki67 is 60%.

Figure 3. Pelvic MRI Intensifying showed irregular soft tissue mass, 2.8 cm * 2.5 cm * 2.7 cm, in internal orifice of cervix a in the coronal position, b in the axial position, c in the sagittal position. MR imaging of the SCCC patient at 15 months after surgery d in the coronal position, e in the axial position, f in the sagittal position.

Figure 4. CT scan showed no abnormity in the lung a before the operation, b after the metastasis of cerebellum.
DISCUSSION

To improve the rate of definitive diagnosis of SCCC, the pathologic diagnostic criteria for neuroendocrine tumours of the uterine cervix have changed over time. In 1994, the World Health Organization (WHO) classified the criteria into two categories: carcinoid and small cell carcinoma. In 1997, Albores-Saavedra et al. proposed a classification of neuroendocrine tumours of the uterine cervix based on classifications for lung cancer. These included small cell carcinoma, large cell neuroendocrine carcinoma, typical carcinoid tumour and atypical carcinoid tumour. In the 2003 WHO classification, like the 1997 classification, 4 categories were listed for neuroendocrine tumours of the uterine cervix: carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma, based on the pattern of lung neuroendocrine carcinoma. However, all the classifications did not detail the morphology within the categories. Thus, detailed descriptions of the morphology of these categories needed further exploration (5).

SCCC is a very rare and aggressive disease that has a high propensity for haematologic and lymphatic metastasis even at an early stage. Between 40% and 60% of patients in early stages experience lymph node metastasis and haematogenous metastasis; recurrence often occurs in the liver, lung, bone, brain, or lymph node within 1 year after diagnosis, leading to treatment failure for most patients with SCCC. SCCC is a rare tumour with a mean annual incidence of 0.06 per 100,000 women, accounting for 1 to 6% of all cervical cancer (6). Due to its rarity and a paucity of knowledge about this disease, there are no identical diagnoses, treatment guidelines, or optimal treatment strategies for this malignancy. Therefore, SCCC remains a therapeutic challenge for clinicians.

The Gynaecologic Oncology Group did not study SCCC between 1982 and 1986 due to insufficient patients to recruit. Then, Abeler et al. found histological similarities between SCCC and SCLC (small cell lung cancer) and proposed 2 hypotheses regarding these similarities. First, a malignant change of argyrophilic cells in the normal uterine cervix turns into SCNEC that secretes polypeptide hormones. Second, multipotential stem cells differentiate into neuroendocrine cells (7). As a result, the treatment regimen was mainly extrapolated from that for SCLC, owing to the histological similarity between the two diseases. However, current studies found that although this malignancy resembles SCLC, the two diseases exhibit varying degrees of immunohistochemical reactivity and respond diversely to the same multimodal regimen (8). Consequently, clinical trials and investigations on a larger scale are still needed to identify optimal treatments for patients with SCCC.

According to the management algorithm for NEC of the cervix, radical surgery is recommended for early-stage disease either primarily or after neoadjuvant chemotherapy. For patients with advanced-stage disease, chemoradiation or systemic chemotherapy is suggested (9).

Radical surgery, including radical hysterectomy and pelvic lymph node dissection, is recommended first for patients with resectable, limited-stage disease. In a clinical document on small cell neuroendocrine carcinoma issued by the Society of Gynaecologic Oncologists, the recommendation for surgical therapy is based on tumour size (figure 5):

- Tumours ≤4 cm (stages I-IIA): Radical hysterectomy with pelvic lymphadenectomy. Followed by adjuvant chemotherapy (etoposide with cisplatin) with or without radiation therapy.
- Tumours >4 cm (stage I-IIA): Either a combination of chemotherapy and radiation therapy or neoadjuvant chemotherapy (platinum-based), followed by surgery if the disease is localized.

However, survival rates using the current therapies are poor after treatment by radical hysterectomy because of the lack of optimal treatment strategies for these patients with early-stage disease (10).

Some authors recommend the use of
chemotherapy following radical surgery for patients with early-stage SCC (11). Treatment regimens with vincristine, doxorubicin, and cyclophosphamide alternating with cisplatin and etoposide (VAC/PE) are commonly used, like in the treatment of SCLC. Given the increased toxicity of the former regimens, EP regimens are preferred because of their better tolerance (12). In the study by Zivanovic et al., patients treated with chemotherapy as part of their treatment regimen have a better 3-year distant recurrence-free survival (13). Kuiji et al. (14) demonstrated significantly better progression-free survival by addition of chemotherapy after radical surgery compared with patients who did not receive chemotherapy. One Korean study showed that primary radical surgery followed by adjuvant chemotherapy is the preferred treatment modality for patients with early-stage SCC. However, the report of Tian et al. (15) suggested that no improved outcomes were found in patients with stage IB1-IIA SCCC after radical hysterectomy followed by adjuvant chemotherapy. Similar findings were reported by Lee et al. The 25.3% 5-year OS rate suggested that radical hysterectomy followed by adjuvant therapy, the usual treatment for other types of cervical carcinoma, is not sufficiently effective for the treatment of SCCC. Therefore, the use of adjuvant chemotherapy for patients with this type of carcinoma may have a sufficient effect; however, adding chemotherapy after radical hysterectomy is controversial at present.

Radiation therapy may play an important role in the treatment of early-stage SCCC. Hoskins et al. reported a 3-year FFS of 80% using chemoradiotherapy in the treatment of 16 patients with SCCC at stages I–II (16). A report by Chen et al. showed a 78% 3-year FFS rate for 14 patients at stages I–II treated with primary radiation therapy and at least 5 cycles of platinum-based chemotherapy (17). Meanwhile, Lee et al. (18) demonstrated that postoperative radiotherapy was harmful. The 5-year survival rate for patients with early-stage SCCC treated with radiotherapy decreased by 13.7%. Two reasons may account for this phenomenon. On one hand, radiotherapy might boost the toxic and adverse effects, hinder the effect of chemotherapy and lower the survival rate. On the other hand, those patients treated with chemoradiotherapy always had one or more high-risk factors. Therefore, given that small cell carcinoma was sensitive to radiotherapy, radiotherapy for SCCC patients with postoperative risk factors is recommended to improve their local control rate.

Currently, prophylactic whole-brain radiation therapy is not recommended routinely in the management of patients with early-stage disease (19). According to the literature, the brain-metastatic rate of SCCC was definitely lower than that of SCLC. Additionally,
Viswanathan et al. concluded that lung metastases may be a necessary precursor to developing brain metastases. In this report, there were no tumours in the brain as the only site of recurrence, and the two patients with brain metastases concurrently had lung metastases. Consequently, cranial imaging examination is recommended only for those SCCC patients with lung metastases. Given the extremely rare incidence of the brain as the sole first metastasis site, prophylactic whole-brain radiation therapy was not conducted following primary tumor treatment. Interestingly, in our case, brain metastasis did serve as the first sole metastasis site (18).

For patients with advanced-stage SCCC, combination chemotherapy with radiation may be recommended. Multidisciplinary treatment therapy is suggested for patients with either widespread metastatic or recurrent SCCC. Regimens using EP or VAC/EP should be considered and selected depending on patients’ presentations (9).

As shown in table 1, several prognostic factors influence the survival rates of SCCC as demonstrated in different studies. In Cohen’s study of 188 patients, stage and use of chemotherapy or chemoradiation were independent predictors of survival among patients with stage I–IIA SCCC (10). Independent prognostic factors identified by Chen et al. included stage, age, race and hysterectomy alone (6). Wang et al. reported two factors: stage and lymph node metastasis, as prognostic (28). Smoking and stage are shown to be prognostic factors for survival in patients with SCCC by Chan et al. (29). The stage is the only common prognostic factor among these studies. Nevertheless, optimal treatment therapy for patients with SCCC remains to be determined, and we often refer to the clinical pattern of pulmonary small cell carcinomas.

In our case, the size of the tumour in the patient with stage IIA was less than 4 cm. The tumour was assigned to stage IIA based on the guidelines of the International Federation of Gynaecology and Obstetrics. She was first given radical surgery treatment; then she received postoperative concurrent chemoradiotherapy. She was treated with 6 cycles of chemotherapy containing etoposide and cisplatin, as in the most commonly used regimen. Fifteen months later, this patient was diagnosed with head metastasis located in the left cerebellum as detected by CT, sized approximately 3 cm in diameter.

**CONCLUSION**

In conclusion, SCCC is a rare, aggressive carcinoma with a poor prognosis, especially for those diseases at an advanced stage and having distant metastasis. Radical surgery is recommended for early-stage disease. For patients with advanced-stage disease, chemoradiation or systemic chemotherapy is suggested (30). The best treatment strategy of SCCC is still unclear and needs further study for exploration and clarification. The case we reported is intended to increase awareness of this rare SCCC metastasis and reinforce the need for more studies and cases, to develop new and more effective treatment for patients with SCCC.

**DECLARATIONS**

**Ethics approval and consent to participate**

The patient we report approved the paper research and volunteered to participate the study. Ethical Committee of Suzhou Municipal Hospital (East Branch) supported the study.

**ACKNOWLEDGEMENT**

This study was subsidized by Research and development program of JiangSu Province (Grant BE2015645) and in part by Grant Z201413 from Scientific Research Project of Health Department of JiangSu Province.

**Conflicts of interest**: Declared none.
Table 1. Review of the literature published for small cell carcinoma of the uterine cervix.

<table>
<thead>
<tr>
<th>Authors</th>
<th>cases</th>
<th>Median age(year)</th>
<th>Stage (FIGO)</th>
<th>Main treatment (study period)</th>
<th>Prognostic factor</th>
<th>Survival outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen et al.</td>
<td>290</td>
<td>45.0</td>
<td>I-Iv b</td>
<td>S±CT±RT (1977-2003)</td>
<td>Age, stage, race, hysterectomy alone</td>
<td>5-year survival rate: 35.7%</td>
</tr>
<tr>
<td>Lee SW et al.</td>
<td>32</td>
<td>45.0</td>
<td>I a-Iv</td>
<td>S±CT±RT (1996-2008)</td>
<td>Haematogenous metastasis</td>
<td>5-year survival rate: 30.5% for early stage</td>
</tr>
<tr>
<td>Cohen et al.</td>
<td>188</td>
<td>42.0</td>
<td>I-Iv b</td>
<td>S±CT±RT (1997-2005)</td>
<td>Stage, use of CT or RT</td>
<td>31.3% for advanced stage</td>
</tr>
<tr>
<td>L. Lan-Fang et al.</td>
<td>43</td>
<td>45.0</td>
<td>I b-Iv</td>
<td>S±CT±RT (1985-2007)</td>
<td>Clinical stage Nodal and haematogenous metastasis</td>
<td>5-year survival rate: 36.8% for stage</td>
</tr>
<tr>
<td>TIAN et al.</td>
<td>96</td>
<td>40.0</td>
<td>I b1- IIa</td>
<td>S±CT±RT (1990-2010)</td>
<td>Stage, lymph node status, deep stromal invasion</td>
<td>9.8% for stage II b-Iv a</td>
</tr>
<tr>
<td>Wang et al.</td>
<td>13</td>
<td>37.0</td>
<td>I b-Iv</td>
<td>S±CT±RT (2006-2010)</td>
<td>Early diagnosis, prompt combination treatment</td>
<td>5-year survival rate: 58.0% for stage I b</td>
</tr>
<tr>
<td>Wang et al.</td>
<td>179</td>
<td>47.0</td>
<td>I-Iv</td>
<td>S, S+CT or RT or CCRT, RT/CCRT (1987-2009)</td>
<td>Stage, lymph node status</td>
<td>5-year survival rate: 51.1% for stage I</td>
</tr>
<tr>
<td>ToKunaga et al.</td>
<td>9</td>
<td>42.0</td>
<td>I b-Iv b</td>
<td>S+CCRT, CCRT (2001-2009)</td>
<td>use of CCRT(VAC/PE)</td>
<td>5-year survival rate: 50.4% for stage I b</td>
</tr>
<tr>
<td>Kuji et al.</td>
<td>52</td>
<td>40.0</td>
<td>I b-Iv b</td>
<td>S±CT, S±CCRT, CCRT (1997-2007)</td>
<td>local therapy + systemic chemotherapy</td>
<td>5-year survival rate: 67.0% for stage I b</td>
</tr>
<tr>
<td>Yuan et al.</td>
<td>38</td>
<td>40.4</td>
<td>I a2- II a1</td>
<td>S±CT (2004-2013)</td>
<td>Parametrical invasion and chemotherapy regimen</td>
<td>2-year OS: 54.7%</td>
</tr>
<tr>
<td>Wang et al.</td>
<td>32</td>
<td>37.0</td>
<td>I b- IIa</td>
<td>S+CT, S+RT (2005-2013)</td>
<td>Tumor size, stage</td>
<td>2-year OS: 56.1%</td>
</tr>
<tr>
<td>Chen et al.</td>
<td>144</td>
<td>45.0</td>
<td>I a- II b</td>
<td>S±CT, CT±RT (1987-2009)</td>
<td>Early stage with tumor ≤2 cm and no LVSI</td>
<td>4-year survival rate: 54.0% for stage I a</td>
</tr>
<tr>
<td>Lee SW et al.</td>
<td>102</td>
<td>50.0</td>
<td>I a-Iv</td>
<td>Preop CT + Postop CT, Postop CT, Postop RT, Postop CCRT (1991-2010)</td>
<td>Stage and use of CT</td>
<td>4-year survival rate: 63% for stage I b</td>
</tr>
<tr>
<td>Zhou et al.</td>
<td>208</td>
<td>40.5</td>
<td>I-II</td>
<td>S±RT, RT (1988-2012)</td>
<td>Stage, age, treatment, lymph node status</td>
<td>5-year survival: OS: 46.4% for treatment of S+RT</td>
</tr>
</tbody>
</table>
REFERENCES


